title: [Effect of cytotoxin interleukin-2-pseudomonas exotoxin 66 on corneal allograft rejection in mice].
abstract: OBJECTIVE
  To study the immunosuppressive effect of the interleukin-2-pseudomonas exotoxin 66(IL-2-PE66) on murine corneal allograft rejection.
  
  
  METHODS
  Thirty-six recipient female BALB/c mice received corneal allografts from C57BL/6 mice and were divided randomly into treatment and control groups. The condition of the grafts was observed twice a week. On days 10, 15, 25 and 35 after the transplantation, the operated eyes were removed for pathological examinations. Peripheral blood samples were also collected for analysis of T cell subsets and T lymphocyte colony forming unit (T-CFU) assay.
  
  
  RESULTS
  The survival time of corneal allograft averaged 15.8-/+2.1 days in the control group and 31.2-/+2.9 days in the treatment group. The CD(4)(+)/ CD(8)(+)/ of the T cell subsets 15 days after the operation was 1.26-/+0.23 in the treatment group and 2.01-/+0.23 in the control group, with T-CFU of 201-/+18.2 and 286-/+16.8, respectively.
  
  
  CONCLUSIONS
  IL-2-PE66 can delay the development of corneal graft rejection, significantly reduce the percentage of T helper cells, and weaken the aggregation of the peripheral T cells.
authors.affiliation: Huiqiao Department, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China. wujing@fimmu.com
authors.forename: Jing
authors.initials: J
authors.lastname: Wu
authors.forename: Jian
authors.initials: J
authors.lastname: Yu
mesh_terms: D000818:Animals; D001426:Bacterial Proteins / Q000627:therapeutic use; D016039:Corneal Transplantation / Q000009:adverse effects*; D003603:Cytotoxins / Q000627:therapeutic use; D005098:Exotoxins / Q000627:therapeutic use*; D005260:Female; D006084:Graft Rejection / Q000188:drug therapy*; D006085:Graft Survival / Q000187:drug effects; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007376:Interleukin-2 / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D011897:Random Allocation; D011993:Recombinant Fusion Proteins / Q000627:therapeutic use*
chemical_list: D001426:Bacterial Proteins; D003603:Cytotoxins; D005098:Exotoxins; D007166:Immunosuppressive Agents; D007376:Interleukin-2; D011993:Recombinant Fusion Proteins; C065698:interleukin 2-PE66(4Glu) protein, recombinant